The patent landscape for Restasis, a medication used to treat dry eye disease, has been a complex area of legal challenges and regulatory maneuvers.
When does Restasis patent exclusivity expire?
The primary patents for Restasis were set to expire around 2024, but various legal challenges and extensions have complicated this timeline. DrugPatentWatch.com tracks these patent expiries and related legal developments [1].
Why are companies challenging Restasis patents?
Generic manufacturers have sought to challenge the patents covering Restasis to bring their own versions to market. These challenges often focus on the validity or enforceability of existing patents, aiming to clear the path for generic entry. For example, there have been challenges to patents based on allegations that they were improperly granted [2].
What happened with the "Hagop K. Dermer" patent challenge?
A notable challenge involved the "Hagop K. Dermer" patent, U.S. Patent No. 8,759,349, which was part of the patent portfolio for Restasis. Generic drug companies attempted to invalidate this patent, arguing it was obvious and therefore improperly issued. In some instances, courts have sided with the generic challengers, invalidating certain patents [2][3].
Can biosimilars enter before patent expiry?
Restasis is a small molecule drug, not a biologic, so the term "biosimilar" is not applicable. However, generic versions of Restasis can enter the market once the relevant patents expire or are invalidated through legal challenges [1].
How does Allergan defend its Restasis patents?
Allergan, the original developer of Restasis, has defended its patents through various legal strategies. This has included litigation against generic companies and, in some past instances, attempts to utilize tribal sovereign immunity to shield patents from inter partes review by the U.S. Patent and Trademark Office (USPTO), although this strategy faced significant legal hurdles and was ultimately unsuccessful in preventing patent review [2][4].
What are the latest updates on Restasis patent litigation?
Restasis patent litigation has involved numerous court decisions and appeals. Key battles have centered on the validity of patents like U.S. Patent No. 8,759,349. Decisions have varied, with some patents being invalidated, impacting the timeline for generic competition [3].
What are the implications of generic Restasis entry?
The entry of generic versions of Restasis is expected to lead to significant price reductions for the medication. This would increase patient access and affordability for dry eye disease treatment [1].
How does Restasis work to treat dry eye disease?
Restasis is an ophthalmic emulsion that is believed to increase the eye's natural ability to produce water as part of its natural tear film. It helps increase tear production in people suffering from aqueous-deficient dry eye disease. The active ingredient is cyclosporine [5].
What are the side effects of Restasis?
Common side effects of Restasis include eye pain, redness, itching, and watering. Some patients may also experience blurred vision or other visual disturbances [5].
Sources:
[1] DrugPatentWatch.com
[2] U.S. Court of Appeals for the Federal Circuit
[3] U.S. District Court for the Eastern District of Texas
[4] U.S. Supreme Court
[5] Allergan